<DOC>
	<DOCNO>NCT01028586</DOCNO>
	<brief_summary>Parkinson 's disease major neurodegenerative disorder progressive loss nigrostriatal dopaminergic neuron . The understanding PD syndrome dopamine ( DA ) deficiency lead introduction clinical practice L-dopa , precursor DA cross blood brain barrier , also use selective inhibitor MAO B , major DA metabolising enzyme man . This double-blind , placebo-controlled , extension trial , parallel-group , randomise , multi-centre , multi national , Phase III trial , compare two dos safinamide ( 50 100 mg p.o . q.a.m . ) versus placebo add-on therapy stable dose single dopamine agonist subject early idiopathic Parkinson 's Disease . The principal objective evaluate time first intervention , previous data suggest safinamide may delay need dopaminergic supplementation .</brief_summary>
	<brief_title>MOTION , Safinamide Early Idiopathic Parkinson 's Disease ( IPD ) , add-on Dopamine Agonist ( Extension Trial 27918 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>1 . The subject complete 24 week Trial 27918 . 2 . The subject successfully complete trial requirement Trial 27918 . 3 . If female , must either post menopausal least 2 year , surgically sterilize undergone hysterectomy , child bear potential must willing avoid pregnancy use adequate method contraception define protocol four week prior , four week last dose trial medication . For purpose trial , woman childbearing potential define : `` All female subject puberty unless postmenopausal least two year , surgically sterile sexually inactive '' . 4 . Subject willing able participate trial provide write , inform consent 1 . If female , subject pregnant lactating . 2 . The subject experience clinically significant adverse effect trial 27918 could put subject risk accord investigator 's opinion . 3 . The subject show clinically significant deterioration participation Trial 27918 . 4 . Motor deterioration trial 27918 require upward titration exist antiparkinsonian medication initiation additional antiparkinsonian medication . 5 . The investigator deem subject 's best interest participate trial 27938 6 . Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>